Entrada Therapeutics treatment of Duchenne muscular dystrophy gets orphan status

Entrada Therapeutics’ DMD exon 44 skipping PMO and proprietary cyclic peptide were granted FDA orphan designation as a treatment of Duchenne muscular dystrophy, or DMD, according to a post to the agency’s website. Reference Link